{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:26Z","timestamp":1789103246268,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metaplastic breast cancer (MBC) is a rare and highly heterogeneous subtype of breast cancer associated with limited treatment options and a poor prognosis. We aimed to characterize the clinical features, pathological findings, treatment patterns, and outcomes of patients with MBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective analysis included nine patients diagnosed with MBC at Hanzhong Central Hospital between January 2016 and July 2025. Clinical data, pathological features, treatment regimens, and follow-up outcomes were comprehensively reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patient ages ranged from 26 to 76 years, with tumor diameters ranging from 1.5\u00a0cm to 7.0\u00a0cm, presenting as irregular hypoechoic masses on ultrasound. Immunohistochemical analysis revealed that the majority of cases (7\/9, 77.8%) were triple-negative; one case (11.1%) was ER-low positive, and one case (11.1%) converted to HER2-positive following neoadjuvant therapy. All patients underwent mastectomy, with some undergoing additional lymph node dissection and radiotherapy. The most common metastatic sites were the liver and brain. At a median follow-up of 24 months (range: 15.7\u201328.4 months), five patients (55.6%) died from distant metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Preoperative diagnosis of MBC remains challenging and relies heavily on postoperative pathological examination. In this single-center series of nine patients, we observed aggressive clinical behavior characterized by a high rate of distant metastasis (liver and brain) and a short-term mortality of 55.6% (five of nine) at a median follow-up of 24 months. However, three patients remained disease-free, and one was alive with metastatic disease at the last follow-up, reflecting the heterogeneous clinical outcomes of this disease. The small sample size and the absence of molecular profiling preclude definitive conclusions regarding optimal treatment sequencing. Our findings underscore the diagnostic complexity, pathological heterogeneity, and urgent need for multicenter collaborative studies with integrated genomic characterization to guide future therapeutic strategies. The molecular data on PIK3CA mutation frequencies and targeted therapeutic approaches discussed in the context of the literature are derived from published studies and were not investigated in our cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1852513","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:35:03Z","timestamp":1789101303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metaplastic breast cancer: a clinicopathological analysis of nine cases highlighting diagnostic challenges and aggressive behavior"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuan","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghua","family":"Kan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiru","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hanzhong Central Hospital","place":["Hanzhong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13058-020-01353-z","article-title":"A comprehensive overview of metaplastic breast cancer: Clinical features and molecular aberrations","volume":"22","author":"Reddy","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B3","article-title":"Metaplastic breast carcinoma. Rare form of mammary cancer","volume":"73","author":"Huvos","year":"1973","journal-title":"N Y State J Med"},{"key":"B4","volume-title":"International Classification of Diseases for Oncology. 3rd ed","author":"Fritz","year":"2000"},{"key":"B5","volume-title":"WHO classification of tumours of the breast. 5th ed","author":"Tan","year":"2019"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28551","article-title":"Metaplastic breast cancer: Characteristics and survival outcomes","volume":"14","author":"Thapa","year":"2022","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0396-RA","article-title":"Metaplastic breast carcinoma: Update on histopathology and molecular alterations","volume":"143","author":"McMullen","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp139","article-title":"Metaplastic breast carcinoma: Clinicopathologic features and prognostic value of triple negativity","volume":"40","author":"Lim","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11020035","article-title":"Metaplastic carcinoma of the breast: Case series of a single institute and review of the literature","volume":"11","author":"Papatheodoridi","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001041","article-title":"Metaplastic breast carcinoma: Clinicopathologic features and recurrence score results from a population-based database","volume":"46","author":"McMurtry","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2500594","article-title":"Differences of clinicopathological features between metaplastic breast carcinoma and nonspecific invasive breast carcinoma and prognostic profile of metaplastic breast carcinoma","volume":"2022","author":"Qiu","year":"2022","journal-title":"Breast J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205544","article-title":"Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma","volume":"72","author":"Li","year":"2019","journal-title":"J Clin Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.11.6221","article-title":"Current progress in the treatment of metaplastic breast carcinoma","volume":"14","author":"Hu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.breast.2019.10.003","article-title":"Comparison of outcomes between metaplastic and triple-negative breast cancer patients","volume":"49","author":"Polamraju","year":"2020","journal-title":"Breast"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph19020311","article-title":"Genomic landscape and therapeutic implications of metaplastic breast carcinoma: Insights from a nationwide database including diagnostic mimickers","volume":"19","author":"Suzuki","year":"2026","journal-title":"Pharm (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102885","article-title":"Therapeutic strategies and landscape of metaplastic breast cancer","volume":"133","author":"Dai","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B17","volume-title":"CSCO breast cancer treatment guidelines","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0398","article-title":"Early and locally advanced metaplastic breast cancer: Presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010\u20132014","volume":"23","author":"Schroeder","year":"2018","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"22070","DOI":"10.1038\/s41598-020-79166-5","article-title":"The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma","volume":"10","author":"Wu","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.912107","article-title":"A retrospective study of the imaging and pathological features of metaplastic breast carcinoma and review of the literature","volume":"25","author":"Jia","year":"2019","journal-title":"Med Sci Monit"},{"key":"B21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12893-021-01375-0","article-title":"Sonographic and pathological features of metaplastic squamous cell carcinoma of the breast: A case series","volume":"21","author":"Ye","year":"2021","journal-title":"BMC Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10737","DOI":"10.1038\/s41467-024-54651-x","article-title":"NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-Jun repression","volume":"15","author":"Reddy","year":"2024","journal-title":"Nat Commun"},{"key":"B23","unstructured":"Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-Paclitaxel in Patients with HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)\n          \n          \n          \n          2026"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.23_suppl.1","article-title":"Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022. Meeting Abstract: ASCO Breakthrough: A Global Summit for Oncology Innovators","volume":"42","author":"Thomas","year":"2024","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18316-3","article-title":"ASO author reflections: Reevaluating treatment sequence in metaplastic breast cancer","volume":"32","author":"Nelis","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.01.006","article-title":"Neoadjuvant chemotherapy for metaplastic breast cancer: Response rates, management, and outcomes","volume":"22","author":"Haque","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17937-y","article-title":"Neoadjuvant versus adjuvant therapy for metaplastic breast cancer: Insights from the national cancer database-is there a winning strategy","volume":"32","author":"Shojaeian","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17938-x","article-title":"Neoadjuvant chemotherapy is not associated with improved overall survival in metaplastic breast cancer regardless of tumor subtype","volume":"32","author":"Reason","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.606","article-title":"Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer","volume":"41","author":"Abuhadra","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:35:20Z","timestamp":1789101320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1852513"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1852513","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1852513"}}